Phase III randomized controlled study of daratumumab, bortezomib, and dexamethasone (DVd) versus bortezomib and dexamethasone (Vd) in patients with relapsed or refractory multiple myeloma (RRMM): CASTOR study

Abstract Number: 
LBA4

Citation: 
J Clin Oncol 34, 2016 (suppl; abstr LBA4)

Author(s): 
Antonio Palumbo, Asher Alban Akmal Chanan-Khan, Katja Weisel, Ajay K. Nooka, Tamas Masszi, Meral Beksac, Ivan Spicka, Vania T.M. Hungria, María-Victoria Mateos, Tomer Martin Mark, Ming Qi, Jordan Mark Schecter, Himal Amin, Xiang Qin, William Deraedt, Tahamtan Ahmadi, Andrew Spencer, Pieter Sonneveld; University of Torino, Torino, Italy; Mayo Clinic Florida, Jacksonville, FL; Universitaetsklinikum Tuebingen der Eberhard-Karls-Universitaet, Tubingen, Germany; Emory University Winship Cancer Center, Atlanta, GA; Fovarosi Onkormanyzat Szent Laszlo Korhaza, Hematologia, Budapest, Hungary; Ankara Universitesi Tip Fakultesi, Ankara, Turkey; Vseobecna Fakultni Nemocnice V Praze, Prague, Czech Republic; Irmandade da Santa Casa de Misericordia de São Paulo, Sao Paulo, Brazil; University Hospital of Salamanca/IBSAL, Salamanca, Spain; New York Presbyterian Weill Cornell Hospital, New York, NY; Janssen Research and Development, LLC, Raritan, NJ; Janssen Research & Development, Raritan, NJ; Janssen Research & Development LLC, Raritan, NJ; Johnson and Johnson, Philadelphia, PA; Alfred Hospital, Melbourne, Australia; Erasmus Medical Center, Rotterdam, Netherlands


ABOUT KATJA WEISEL, MD

Professor of Internal Medicine University Hospital Tübingen Head, Tübingen University Myeloma Center Tübingen, Germany

Previous Post
ASCO 2016: PAVO study -- Dr. Saad Usmani
Next Post
ASCO 2016: Multiple Myeloma Overview -- Dr. Sagar Lonial

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.